Ranitidine analog, JWS-USC-751X, enhances memory-related task performance in rats

Drug Development Research

Volumn 47, Issue 2, 1999, Pages 97-106

  Terry Jr , Alvin V ^a,b,d   Gattu, M ^a   Buccafusco, J J ^a,b   Sowell, J W ^c   Kosh, J W ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

Acetylcholinesterase; Cholinergic; Histamine; M2 receptor; Memory; Rat

Indexed keywords

3 [[[2 [[(5 DIMETHYLAMINOMETHYL) 2 FURANYL]METHYL]THIO]ETHYL]AMINO] 4 NITROPYRIDAZINE; ACETYLCHOLINESTERASE; CYTISINE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; RANITIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COGNITION; DISCRIMINATION LEARNING; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG RECEPTOR BINDING; FREQUENCY ANALYSIS; LATENT PERIOD; MALE; MEMORY; NONHUMAN; PASSIVE AVOIDANCE; RAT; SPATIAL MEMORY; TASK PERFORMANCE;

EID: 0344758441     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199906)47:2<97::AID-DDR5>3.0.CO;2-I     Document Type: Article

References (32)

1. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
2. Coyle JT, Donald LP, Delong MR. 1983. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219:1184-1186.
3. 2 antagonists: novel structures and pharmacology. Life Sci 52:497-503.
4. 2 muscarinic receptor. Nature 319:405-408.
5. Engström C, Undén A, Ladinsky H, Consolo S, Bartfai T. 1987. BM-5, a centrally active partial muscarinic agonist with low tremorogenic activity. Psychopharmacology 91:161-167.
6. Gellerman LW. 1933. Chance order of alternating stimuli in visual discrimination experiments. J Genet Psychol 42:207-208.
7. 3H]-dopamine release from synaptosomes prepared from mouse striatum. J Neurochem 59:848-856.
8. Kosik KS. 1992. Alzheimer's disease: a cell biological perspective. Science 256:780-783.
9. 3H)AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. Brain Res 496:285-294.
10. Mash DC, Flynn DD, Potter LT. 1985. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115-1117.
11. Miyazaki S, Imaizumi M, Onodera K. 1995. Ameliorating effects of histidine on scopolamine-induced learning deficits using an elevated plus-maze test in mice. Life Sci 56(19)1563-1570.
12. Morris RGM. 1984. Development of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60.
13. Nilsson L, Adem A, Hardy J, Wimblad B, Nordberg A. 1987. Do tetraaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? J Neurol Transm 70:357-368.
14. 2 receptor antagonist AF-DX 116 improves memory. Brain Res 524:72-76.
15. Palmer AM. 1996. Neurochemical studies of Alzheimer's disease. Neurodegeneration 5(4):371-391
16. 1 muscarinic receptors to G protein in Alzheimer's disease. In: Alzheimer's disease and associated disorders. New York: Raven Press. 5:163-172.
17. Perry EK. 1986. The cholinergic hypothesis: ten years on. Br Med Bull 42:63-69.
18. Quirion R. 1993. Cholinergic markers in Alzheimer's disease and the autoregulation of acetylcholine release. J Psychiatr Neurosci 18:226-234.
19. 2-muscarinic receptor antagonist in aged memory-impaired rats. J Neurosci 15(2):1455-1462.
20. Rogers SL, Friedhoff LT. 1994. E2020 improves cognition and quality of life in patients with mild-to-moderate Alzheimer's disease: results of a phase-II trial. Neurology 44(suppl 2):165.
21. 3H) (-)-nicotine to rat brain membranes and its inhibition by analogues of nicotine. Neuropharmacology 27:235-241.
22. Schneider LS. 1993. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology 43(suppl 4):S64-S79.
23. Schneider LS. 1994. Tacrine development experience: early clinical trials and enrichment and parallel designs. Alzheimer Dis Assoc Disord 8(suppl 2):S12-S21.
24. Schwarz RD, Davis RE, Gracon S, Hoover T, Moos WH, Pavia MR. 1991. Next generation tacrine. Neurobiol Aging 12:185-187.
25. Selkoe DJ. 1993. Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 16:403-409.
26. Shapiro G, Floersheim P, Boelsterli J, Amstutz R, Bolliger G, Gammenthaler H, Gmelin G, Supavilai P, Walkinshaw M. 1992. Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor. J Med Chem 35:15-27.
27. Smith CPS, Hunter AJ, Bennett GW. 1994. Effects of (R)-α-methylhistamine and scopolamine on spatial learning in the rat assessed using a water maze. Psychopharmacology 114:651-656.
28. Spokes EGS. 1981. The neurochemistry of Huntington's chorea. Trends Neurochem Sci 4:115-118.
29. Terry AV Jr, Buccafusco JJ, Jackson WJ, Zagrodnik S, Evans-Martin FF, Decker MW. 1996. Effects of stimulation or blockade of central nicotinic-cholinergic receptors on performance of a novel version of the rat stimulus discrimination task. Psychopharmacology 123:172-181.
30. Terry AV Jr, Buccafusco JJ, Decker MW. 1997. Cholinergic channel activator, ABT-418 enhances delayed response accuracy in rats. Drug Dev Res 40:304-312.
31. Terry AV Jr, Williamson R, Gattu M, Beach JW, McCurdy CR, Sparks JA, Pauly JR. 1998. Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Neuropharmacology 37(1):93-102.
32. Valli MJ, Yunzhao T, Kosh JW, Chapman JM Jr, Sowell JW Sr. 1992. Synthesis and cholinergic properties of N-aryl-2-[[[5-[(dimethylamino)methyl]-2 furanyl] methyl]thio]ethylamino analogs of ranitidine. J Med Chem 35:3141-3147.